Swiss Dermatology Network of Targeted Therapies (SDNTT)

Sponsor
Swiss Dermatology Network for Targeted Therapies
Study ID
NCT01706692
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Adalimumab — BIOLOGICAL
    all dosages, frequencies and durations prescribed
  • Etanercept — BIOLOGICAL
    all dosages, frequencies and durations prescribed
  • Infliximab — BIOLOGICAL
    all dosages, frequencies and durations prescribed
  • Ustekinumab — BIOLOGICAL
    all dosages, frequencies and durations prescribed
  • Cyclosporine A — DRUG
    all dosages, frequencies and durations prescribed
  • Fumaric acids — DRUG
    all dosages, frequencies and durations prescribed
  • Methotrexate — DRUG
    all dosages, frequencies and durations prescribed
  • Other anti-psoriatic systemic treatments — DRUG
    all dosages, frequencies and durations prescribed

Study Details

The purpose of this study is to evaluate the long-term course of patients with psoriasis and psoriatic-arthritis in systemic treatments such as, methotrexate, cyclosporin A, fumaric acids, acitretin, systemic PUVA, etanercept, infliximab, adalimumab and ustekinumab. A patient will be included at first initiation of the treatment and will remain in the registry for 10 years, regardless of subsequent therapy. The registry will also evaluate safety clinical outcomes and health related quality of life.

Key Dates

Start date
Feb 28, 2011
Status verified
Nov 2024
Primary completion
Mar 15, 2032
Completion
Mar 15, 2032

Study Design

Enrollment
1,121 participants (estimated)

Arms

  • Arm: Adalimumab
    Intervention: Biological: Adalimumab, all dosages, frequencies and durations prescribed
  • Arm: Etanercept
    Intervention: Biological: Etanercept, all dosages, frequencies and durations prescribed
  • Arm: Infliximab
    Intervention: Biological: Infliximab, all dosages, frequencies and durations prescribed
  • Arm: Ustekinumab
    Intervention: Biological: Ustekinumab, all dosages, frequencies and durations prescribed
  • Arm: Cyclosporine A
    Intervention: Drug: conventional systemic: Cyclosporine A, all dosages, frequencies and durations prescribed
  • Arm: Fumaric acids
    Intervention: Drug: conventional systemic: Fumaric acids, all dosages, frequencies and durations prescribed
  • Arm: Methotrexate
    Intervention: Drug: conventional systemic: Methotrexate, all dosages, frequencies and durations prescribed
  • Arm: Other anti-psoriatic systemic treatments
    e.g.: Intervention: Drug: conventional systemic: Acitretin or Systemic phototherapy (PUVA), all dosages, frequencies and durations prescribed

Primary Outcome Measure

Psoriasis Area Severity Index (PASI) [ Time Frame: every 6 months for 10 years ]

Related Studies